2015 was a year that marked a number of notable milestones and achievements for IPPOSI.

Our key strategic activity in 2015 was to revise our overall strategy for the next four years. In addition, following the departure of Eibhlin Mulroe in April to ICORG (now Cancer Trials Ireland), it was imperative that the board act swiftly to appoint a new CEO who could build on Eibhlin’s excellent work and develop a new strategy for the organisation. This we achieved with the appointment of Dr Derick Mitchell.

Derick has come to IPPOSI from the EU Joint Programme for Neurodegenerative Disease Research (JPND) and indeed was based in IPPOSI in a previous role as the Executive Manager of the pan-European Biobanking Forum of BBMRI. Since Derick’s arrival in August IPPOSI has successfully obtained multi-annual funding from the Department of Health (via the Health Research Board), following a very positive international peer review of our four-year business plan. With our new strategy now in place we look forward to a solid and sustainable future for the IPPOSI role in the health policy, regulation and research agendas.

Similarly we must thank Eibhlin for her eight wonderful years that have seen IPPOSI grow from a fledgling organisation into an effective and recognised player with a unique perspective on the cross-cutting issues of concern to Irish patients, scientists and other health partners and industries.

In 2015, IPPOSI once again secured a round table engagement between our members and the Secretary General of the Department of Health on the topic of Health Information in Ireland. Another notable success this year was an excellent and diverse panel for an Orphan Drugs Round Table Meeting in February ahead of Rare Disease Day 2015.

As it was another year of loyal support from our membership in all our activities, I would like to extend my thanks for your continued support and I look forward to more enlightening discussions, partnerships and new thinking going forward under our new strategy.

Godfrey Fletcher

Chairperson’s Welcome

The Board of IPPOSI consists of elected members from each of the participant sectors. Patient organisations are represented by eight members, with science and industry members each having six seats.

The Chairperson is always a representative from a patient organisation.

The Board of Directors

The Board of Directors of IPPOSI met five times in 2015. The Board manages and oversees the organisation and where it should focus its efforts in order to achieve goals and objectives. The Board are responsible for major decisions on spending, year on year. IPPOSI Directors will continue to develop and grow the Board ensuring there is a rotation of one third of the Board every year according to our Memorandum and Articles of Association. While membership of IPPOSI is open to all those with an interest, the current Directors from each of the three sectors also work to identify appropriate targets for membership.

Finance Committee

The Finance Committee is a subcommittee of the Board and is made up of the Chairperson, Treasurer and Secretary of the Board. The Committee interacts with the CEO on matters related to financial management, staff remuneration and other HR issues. A full record of our financial information as of the 31st December 2015 is available in this report.

EUPATI National Platform, Ireland

All IPPOSI members are members of the EUPATI National Platform in Ireland (the national network of the European Patients’ Academy for Therapeutic Innovation). A subcommittee of the Board oversees the management of the EUPATI National Platform and helps sets the strategic direction around patient involvement in Irish medicines research and development. The subcommittee is led by a patient Chairperson, and supported by several other patient, academic and industry representatives.
2015 marked the final year of IPPOSI’s pre-existing strategic plan and my own first six months as CEO. Our vision of ensuring patients in Ireland have prompt access to new and developing innovative therapies remains core to the organisation and to the work carried out in 2015.

Following the publication of the National Rare Disease Plan in 2014, IPPOSI continues to provide oversight of the plan implementation, with particular focus on access to Orphan Medicines & Technologies. A round-table event in March brought over 100 IPPOSI members to the table to outline how we can move this area forward, under the recommendations in the plan.

As ever IPPOSI reacted to an evolving health environment and in June the Annual Round Table Meeting with the Secretary General was hosted on the topic of Health Information. Another highlight was an IPPOSI-facilitated patient-researcher workshop as part of the EU COST Action on Connected Health Research (ENJECT) training course – a real example of patient involvement in action!

EUPATI featured heavily in the IPPOSI workload in 2015, particularly with our bringing the EUPATI Annual Conference to Dublin. All of this work was facilitated by Laura Kavanagh, who has spearheaded the development of National Platforms (quasi IPPOSI-like organisations) all over Europe, that can implement a model of partnership and co-operation between patients, science, industry and government, as IPPOSI has done for the past several years.

Here in Ireland we continue to deliver a range of training and information events, with Outcome Reports supporting these meetings as necessary. The IPPOSI website has been upgraded and a new-look monthly newsletter continues to be published thanks to the work of our Communications Manager, Ken Rogan.

IPPOSI is in a very confident position for 2016 and undergoing a period of growth and optimism for our future. We now know that IPPOSI is a unique model where patients lead discussions between all stakeholders. Queries from all over the world have been received about how we make IPPOSI work. The answer is simple - we work together with a dedicated group of stakeholders who believe patients can lead the agenda.

I would like to express my gratitude to all of you, our members for continuing to be involved and supporting IPPOSI in its mission to bring the patient perspective into decision making. Looking forward to working with you all in the year ahead!
Some events in 2015

Members of EUPATI National Platform Ireland (L-R):
Back row: Derick Mitchell, IPPOSI; Joan Jordan, MS Ireland; Rachel Lynch, FibroIreland; Sinead Tuite, Merck; Laura Ravanagh, IPPOSI; John Dowling, Men Against Cancer;
Seated: Dr Fiona Manning, RCSI; Julie Power, Vasculitis Ireland; Katie Murphy, CF Ireland

Privacy Impact Assessment for Individual Health Identifiers Consultation (L-R): Richard Corbridge, Chief Information Officer, HSE, CEO eHealth Ireland; Claire Sanderson, IG Solutions; Dr Derick Mitchell, IPPOSI

EUPATI Fellows & Trainees

Top row: Damien Peelo, COPD Support Ireland; Joan Jordan, MS Ireland; Caitriona Dunne, Fighting Blindness; Sharon Thompson, unaffiliated
Second row: Katie Murphy, CF Ireland; Julie Power, Vasculitis Ireland; Norsin O’Neill, unaffiliated; Rachel Lynch, FibroIreland. Not represented here, but also a EUPATI Trainee is John Dowling, Men Against Cancer.

The EUPATI Toolbox

www.eupati.eu
Training & patient involvement

IPPOSI continued to bring a patient perspective to clinical research through its dual approach of preparing both the research environment to accept the input of patients, and preparing patients to provide that input in an informed way. The most obvious output of this approach continues to be our annual ‘clinical research for non-clinical researchers’ training event, which was held in the offices of Boston College on St Stephen’s Green.

More than 40 attendees – patients, researchers, members of industry – participated in the event that saw Siobhan Gaynor (Genable), Dr Gloria Crispino (StatisticaMedica) and Dr Robert O’Connor (Irish Cancer Society) cover the clinical research process, statistical analysis, and the Irish research environment respectively. It continues to be a valuable event for our members that attracts new participants and speakers year on year.

Our IPHA Code of Practice for Pharmaceutical Companies briefing was held in EU House, Dublin where Dr Rebecca Cramp from IPHA provided an informative and engaging presentation that triggered much discussion among attendees. The participants were also treated to a presentation from Dr Michaela Davis from UCD’s PACE-R / SSRA (Summer Student Research Awards) programme and one of her former students, Maeve Jones-O’Connor, which alerted patient members to the possibility of engaging medical students in research projects that directly address their conditions and concerns.

IPPOSI also delivered the closing lecture to UCD medical students as part of the popular elective module on Rare Diseases. Impressions about the course, and the rare disease community in Ireland, were gathered from students to inform next year’s module.

Finally, through our involvement in the EU COST Action on Connected Health Research (ENJECT), IPPOSI facilitated a patient-researcher workshop as part of the ENJECT training course in December in University College Dublin. The workshop was a real example of ‘patient involvement in action’ and focused on routine translation of data into knowledge and methodological perspectives when working with patient populations. The 3-day course was organised by the ENJECT Cost Action and was co-hosted by the Insight Centre for Data Analytics and ARCH. An IPPOSI patient video from the event with Mags Mularney of Move for Parkinson’s is available on the IPPOSI website.

EUPATI

In 2015 much of our work in EUPATI contributed to bringing a patient perspective to clinical research here in Ireland and abroad around Europe.

2015 saw the evolution of Ireland’s EUPATI National Platform where key members of the research community and the Expert Patient Trainees joined forces to build on the momentum of the Expert Patient Training Course to explore how new patient involvement opportunities might be identified and exploited in Ireland.

IPPOSI was also heavily involved in hosting the EUPATI

Bringing a patient’s perspective to clinical research

Annual Conference in Dublin Castle in April 2015. Hundreds of delegates from Ireland and around Europe convened to discuss the Patient Expert Training Course, making ENPs workable and sustainable, and how to build a voice online. The IPPOSI membership was very well represented both as presenters and vocal audience members.

2015 saw another four Irish patients successfully apply to the EUPATI Patient Expert Training Course, so congratulations to Katie Murphy, Joan Jordan, John Dowling, and Caitriona Dunne for achieving this. The trainees undergo an intensive e-learning schedule and two face-to-face sessions and we look forward to reaping the rewards of their knowledge in terms of strengthening the patient voice and developing opportunities for patient involvement in Ireland.

Another key component of the EUPATI programme is the EUPATI Toolbox – an online resource of more than 3,000 web pages, presentations, and videos about every element of clinical research. This toolbox was adapted from the course material of the Patient Expert Training Course, thereby allowing patients in Ireland and all over Europe to understand the research process and thus engage with it more effectively. IPPOSI played a significant role in the development of the Toolbox by being one of the patient members of an editorial board that reviewed every piece of content from a patient’s perspective.

HRB-CRCI and HRB-TMRN

In 2015, IPPOSI formed strategic partnerships with two key organisations supported by the Health Research Board to further develop the patient voice within the emerging Irish clinical research infrastructure. As a member of the international advisory board of HRB’s Trials Methodology Research Network (HRB-TMRN), IPPOSI was asked to be part of a (ultimately successful) HRB-TMRN Knowledge Exchange and Dissemination proposal on the area of recruitment to clinical trials. This KEDS grant has since expanded to become a joint HRB-TMRN + James Lind Alliance partnership which is aiming to produce the top ten unanswered questions (uncertainties) for those involved in recruitment to clinical trials. IPPOSI also held a number of exploratory meetings with the newly established HRB-CRCI (Clinical Research Co-ordination Ireland) to discuss how clinical trials activity might be enhanced in Ireland.
Rare Diseases

Following on from the launch of the National Rare Disease Plan for Ireland in 2014, the focus for 2015 was very much on the implementation of key plan provisions, most notably the establishment of the National Rare Disease Office (NRDO), which would provide a focal point for people with rare diseases in Ireland. In spite of a challenging funding environment, and thanks to the work of everyone involved, funding for the NRDO was secured and the office opened in June 2015.

To ensure this, and in order to follow through on the other recommendations of the plan, IPPOSI met with the HSE, and was part of delegation that met with Minister Leo Varadkar in March 2015. Just prior to this, IPPOSI was part of a panel presenting to the Joint Oireachtas Committee on Health and Children concerning the Implementation of the National Rare Disease Plan.

All of this activity converged around Rare Disease Day 2015 (Feb 28th), and in order to celebrate this and highlight the issue of medicines for people with rare diseases, IPPOSI hosted a round-table meeting entitled “Orphan Drugs: Access in Ireland”. The event was a great success, attracting more than 100 delegates and some excellent speakers including Katie Murphy (CF Ireland), Josie Godfrey (NICE UK), Roisin Adams (NCPE), Greg Pastores (Mater Hospital), Fred Doherty (Genzyme) and Prof David Smith (RCSI).

Overall the event was very well received by all of our member groups, and an Outcome Report was subsequently published to capture the key points, ethical considerations, the importance of patient involvement, learning from the UK experience, transparency, ring-fenced funding, managed-entry, patient registries, clinical trials, and costs.

IPPOSI continued to sit on the National Rare Disease Plan Oversight Committee, and under the remit of the national plan, we partnered with MRCG & GRDO to organise the EUROPLAN 2 meeting in Dublin in September. Speakers included IPPOSI’s Derick Mitchell, Dr John Devlin (Department of Health), Avril Daly (GRDO/Fighting Blindness), Philip Watt (CF Ireland/MRCG), Prof Eileen Treacy (Temple St CUH), Tony Heffernan (Saoirse Foundation), and Avril Kennan (Debra Ireland).

Health Information

The appropriate collection, storage and use of health information and patient data has been a key area of focus for IPPOSI over the past few years, and that trend continued in 2015 with this topic being the focus of the ‘Annual Round Table Meeting with the Secretary General’ in late May. A major focus continues to be the EU’s upcoming Data Protection Regulation, addressed at the 2015 meeting by Dr Graham Love (HRB), Garrett O’Neill of the Data Protection Commissioner’s Office, and by Prof Seamas Donnelly (TCD).

The issue of data protection was preceded by a policy briefing from the Secretary General, Mr Jim Breslin, and by an outline of HSE priorities in this area as delivered by the HSE’s Chief Information Officer, Richard Corbridge whose

Influencing policy impacting research and access to innovative therapies

priorities include large-scale eHealth initiatives such as Individual Health Identifiers, e-referrals, and electronic health records, among others.

The second part of the round table addressed the issue of patient registries where perspectives from patients, science and industry were provided thanks to the contributions of Godfrey Fletcher (Cystic Fibrosis Registry of Ireland), Maria Meehan (Fighting Blindness), Prof Doug Veale (UCD), Rachel Flynn (HIQA) and Linda Tormey (Bayer). The Outcome Report arising from this meeting is available on the IPPOSI website.

IPPOSI continued to interact with Richard Corbridge’s office through a number of consultations regarding the Privacy Impact Assessment for the Individual Health Identifier. Both the IPPOSI board (via a written submission) and the broader IPPOSI membership (via a consultation event in the Royal Academy of Ireland) were consulted with in Autumn 2015. The event was a success and you can see our submissions on the IPPOSI website. IPPOSI CEO Derick Mitchell also took up a seat on the eHealth Ireland Committee in October, and we are pleased that a good working relationship has continued between IPPOSI and the HSE/eHealth Ireland.

Submissions

IPPOSI made a number of additional submissions in 2015, including:

- The Government Strategy for Science, Technology & Innovation
- Health Information & Quality Authority (HIQA) budget impact – in IPPOSI’s capacity as a member of the HIQA HTA advisory Board
- National Midwifery Board of Ireland / ONMSD HSE Communication to the Expert Advisory Panel for Medicines

HTA Training

Once again IPPOSI partnered with the National Centre for Pharmacoeconomics (NCPE) to deliver a patient-only training event in the Science Gallery, Trinity College, in March. Thanks are due, as ever, to Dr Roisin Adams, Dr Cathal Walsh, and their colleagues from the NCPE who guided our members though complex concepts such as ICER, QALY and the factors at play in making recommendations on the reimbursement of new medicines.
Internationally, IPPOSI’s work on the EUPATI project continues to maintain a large degree of awareness of our organisation among key European and international groups. Domestically, IPPOSI relies on strategic presentations, events, and media coverage arising to inform key audiences of our work. In this regard, one of the key events in 2015 was the IPPOSI/IPHA ‘Innovation and Partnership’ meeting in the Royal College of Physicians in June.

IPPOSI Board member Ms Avril Daly spoke on behalf of IPPOSI in what was an impressive event that attracted good numbers of our members, and excellent international speakers. IPPOSI’s role was subsequently covered in the Irish Times thanks to an article written by health journalist Priscilla Lynch.

IPPOSI representatives made a number of other presentations throughout the year, including:

- Joint Oireachtas Committee for Health and Children (February)
- EUPATI Annual Conference (April)
- EUROPLAN 2 (September)
- eHealth Summit (September)
- Health Informatics Society of Ireland conference (October)
- MMI Prostate Cancer Research Information Day

**Committees**

In addition to IPPOSI’s existing membership of major health-related committees, in 2015 we took a seat on:

- The Royal Irish Academy’s Life & Medical Sciences Committee
- The eHealth Ireland Committee
- The international advisory board of the HRB-TMRN (Trials Methodology Research Network)

**Media**

Highlights for 2015:

- Media coverage from the EUPATI Annual Conference in April
- Coverage of the IPPOSI / IPHA ‘Innovation & Partnership’ event in June

**Webinars**

IPPOSI / EUPATI hosted three webinars in 2015:

- Patient contributions to ethical reviews (March)
- Health Technology Assessment (September)
- Interaction between patients and other stakeholders in the medicine development process (November)

**Videos**

IPPOSI continues to record vox pops interviews of speakers and stakeholders to provide a snapshot of critical issues pertaining to events. Video interviews were recorded for:

- Orphan Drugs: Access in Ireland Round Table Meeting
- Health Information Round Table Meeting
- Privacy Impact Assessment on Individual Health Identifiers members consultation
- The EJECT researcher-patient workshop on Connected Health

**Website and Social media**

- The IPPOSI website continues to update the broader public on our activities. The website underwent a first-phase re-design to better showcase and navigate the multiple aspects of our work. Phase two of the re-design is due in 2016.
- Twitter – our number of followers continues to grow steadily
- Flickr – IPPOSI established a Flickr page where we upload albums of pictures from our events
- Slideshare – the IPPOSI slideshare account allows you to review all presentations made at IPPOSI events and all presentations made by IPPOSI at other events
- Vimeo – all of IPPOSI’s vox pops videos, patient diaries, and other videos are available on our Vimeo page
## Profit and loss account (continued)
Financial year ended 31 December 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>Turnover</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>326,486</td>
<td>288,825</td>
</tr>
<tr>
<td>Direct costs</td>
<td></td>
<td>(225,200)</td>
</tr>
<tr>
<td>Gross profit</td>
<td></td>
<td>101,286</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td></td>
<td>(64,994)</td>
</tr>
<tr>
<td>Operating profit</td>
<td>5</td>
<td>36,292</td>
</tr>
<tr>
<td>Other interest receivable and similar income</td>
<td>7</td>
<td>30</td>
</tr>
<tr>
<td>Profit on ordinary activities before taxation</td>
<td></td>
<td>36,322</td>
</tr>
<tr>
<td>Tax on profit on ordinary activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit for the financial year</strong></td>
<td></td>
<td>36,322</td>
</tr>
</tbody>
</table>

All the activities of the company are from continuing operations.

The company has no other recognised items of income and expenses other than the results for the financial year as set out above.

## Balance sheet
As at 31 December 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td><strong>Fixed assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tangible assets</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,431</td>
<td>2,687</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2,431</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,292</td>
<td>4,605</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>222,206</td>
<td>264,283</td>
</tr>
<tr>
<td></td>
<td>223,498</td>
<td>268,888</td>
</tr>
<tr>
<td><strong>Creditors: amounts falling due within one year</strong></td>
<td>10</td>
<td>(95,179)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net current assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>128,319</td>
<td>91,739</td>
</tr>
<tr>
<td><strong>Total assets less current liabilities</strong></td>
<td>130,750</td>
<td>94,426</td>
</tr>
<tr>
<td>Net assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>130,750</td>
<td>94,426</td>
</tr>
<tr>
<td><strong>Capital and reserves</strong></td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Profit and loss account</td>
<td>130,750</td>
<td>94,426</td>
</tr>
<tr>
<td>Members funds</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>130,750</td>
<td>94,426</td>
</tr>
</tbody>
</table>
PATIENTS’ ORGANISATIONS

22q11 Support Group Ireland
Action Duchenne
Alpha One
Alzheimers Society of Ireland
Angelman Syndrome Ireland
Arthritis Ireland
Asthma Society of Ireland
Ataxia Ireland
Bone Cancer Research Trust
Brain Tumour Ireland
CATTS Ireland
Children In Hospital Ireland
Chronic Pain Ireland
Co-operation and Working Together (CAWT) Cross Border Health & Social Care
COPD Support Ireland
Cystic Fibrosis Association of Ireland
Cystic Fibrosis Registry of Ireland
Cystinosis Ireland
DEBRA Ireland
Diabetes Federation of Ireland
Disability Federation of Ireland
Dublin Simon Community
Duchenne Ireland
Ehlers Danlos Syndrome Awareness Ireland
Endometriosis Association of Ireland
Epilepsy & Pregnancy Register South of Ireland
Fabry Ireland
Fighting Blindness
GRDO - Genetic & Rare Disorders Organisation
Huntington’s Disease Association of Ireland
Ileostomy & Internal Pouch Support Group
IMD Action Group
Irish Cancer Society
Irish Fragile X Society
Irish Haemophilia Society
Irish Heart Foundation
Irish Hospice Foundation
Irish Kidney Association
Irish Lung Fibrosis Association
Irish ME/CFS Association
Irish MPS Society
Irish Neonatal Health Alliance
Irish Osteoporosis Society
Irish Patients Association
Irish Premature Babies
Irish Raynaud’s & Scleroderma Society
Irish Sarcoïdosis Support Network (ISARC)
Irish Skin Foundation
Irish Society for Mucopolysaccharide Diseases
Irish Thoracic Society
Join Our Boys Trust
Lauralynn, Ireland’s Children’s Hospice
Marie Keating Foundation
Men Against Cancer
Meningitis Research Foundation
Migraine Association of Ireland
Motor Neurone Disease Association
Move4Parkinson’s Foundation
MRCG - Medical Research Charities Group
Multiple Myeloma Ireland
Multiple Sclerosis Ireland
Multiple System Atrophy Trust
Muscular Dystrophy Society of Ireland
Myasthenia Gravis Association
NCBI - National Council for the Blind Ireland
Neurological Alliance of Ireland
OACS Ireland /FACs Forum Ireland
OvaCare
Parkinsons Association Of Ireland
Pituitary Foundation
Pompe Disease - Patient
Prader-Willi Syndrome Association Ireland
PSPA Ireland
Pulmonary Hypertension Association of Ireland
Rehabcare
Rett Syndrome Association of Ireland
Shine Ireland
Sickle Cell & Thalassaemia Ireland (SCTI)
Tarlov Cyst Disease - Patient
The Saoirse Foundation
Vasculitis Ireland Awareness

INTERNATIONAL PATIENT GROUPS

EPOS
Genetic Alliance UK
NIRDP
Pain Alliance Europe
PID UK (Primary Immunodeficiency UK)
Rare Disease UK
URDDAD Foundation (formally Terry Hoey)

UNIVERSITIES & COLLEGES

DCU
Hibernian College
Mater Dei Institute of Education - DCU
NUI Galway
RCSI
Royal Victoria Eye & Ear Hospital
TCD
UCD
University College Cork
University of Ulster
WIT - School of Health Sciences
Newcastle University

INDUSTRY

AbbVie
Alexion
Bayer
BioMarin
Boehringer Ingelheim Ireland Ltd
Celgene
Eli Lilly
Genzyme
GSK
ICON
Janssen Cilag
Merck Serono (Ireland) Limited
MSD
Novartis
Pfizer
Roche
Shire
**RESEARCH CENTRES/DEPTs**

BioBank Ireland Trust  
Cancer Trials Ireland (formally ICORG)  
Centre for Health Informatics, TCD  
Cork Cancer Research Centre  
Dublin Centre for Clinical Research  
Institute for Molecular Medicine at St. James Hospital  
Mater University Hospital - National Pulmonary Hypertension Unit/PHA  
Molecular Medicine Ireland  
National Paediatric Mortality Registry  
NCSRN - Ireland (Irish Heart Foundation)  
Oncology Clinical Trials Cork University  
RCU Research Office  
Research Foundation, Royal Victoria Eye & Ear Hospital  
School of Nursing and Midwifery, TCD  
School of Psychology, NUI Galway  
TRIL - Technology Research Centre for Independent Living  
Trinity EngAGE Centre for Research on Ageing, TCD  
UCD Conway Institute  
UCD Research  
UCD School of Law  
UCD School of Medicine and Medical Science  
INSERM, ECRIN

**HOSPITALS**

All Ireland Institute of Hospice & Palliative Care (AIIHPC) - Our Lady’s Hospice  
AMNCH - The Adelaide and Meath Hospital  
Beaumont hospital - RCSI  
Belfast City Hospital  
Belfast Trust - Regional Immunology service  
Children’s University Hospital Temple Street  
Clinical Research Centre Beaumont Hospital  
Coome Women & Infants University Hospital  
Dublin Dental School & Hospital  
Mater Hospital  
Midland Regional Hospital  
OLCHC  
St Patricks Mental Health Services  
St Vincent’s University Hospital  
St. James’s Hospital - Department of Immunology  
Tallaght Hospital  
Temple Street Children’s University  
The Mater Foundation - Mater Hospital

**ETHICS COMMITTEES**

AIT Research Ethics committee  
EMA (European Medicines Agency) Paediatric Committee  
Ethics (Medical Research) Committee  
Beaumng Hosp.

**STATE AGENCIES**

Enterprise Ireland  
FORFAS  
Health Information and Quality Authority  
Health Research Board  
IDA  
Irish Medicines Board  
SFI  
HSC NI - Health & Social Care Services in Northern Ireland

**ACADEMIC INSTITUTIONS**

ICGP - Irish College General Practitioners

**GOVERNMENT**

Department of Health  
Joint Oireachtas Committee on Health and Children  
Minister for Health  
Office of the Chief Medical Officer  
Seanad Éireann  
Secretary General Department of Health  
Sinn Fein

**OTHER**

Data Protection Office  
EFGCP  
Eighth Day  
EUPATI  
EURORDIS  
Hibernia College, Sch. Health Sc.  
IMSTA — Irish Medical and Surgical Trade Association  
Institute of Public Health in Ireland  
IPHA - Irish Pharmaceutical Healthcare Association  
Minimate Limited  
NTMA - National Treasury Management Agency  
Prospectus

**NATIONAL CENTRES, AGENCIES & PROGRAMMES**

ISQSH - Irish Society for Quality and Safety in Healthcare  
National Advocacy Unit  
National Cancer Control Programme (NCCP)  
National Cancer Registry Ireland  
National Centre for Inherited Metabolic Disorders  
National Centre for Medical Genetics  
National Children’s Research Centre  
NCPE National Centre for Pharmacoeconomics  
OHCAR - the National Out-of-Hospital Cardiac Arrest Register  
EUROCAT  
NICE